Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome-Reference-Cited by-同舟云学术

Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome

Published:2020-02-25 Issue:8 Volume:323 Page:713
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Shankar-Hari Manu¹²,Calfee Carolyn S.³

Affiliation:

1. School of Immunology and Microbial Science, Kings College London, London, United Kingdom

2. Guy’s and St Thomas’ NHS Foundation Trust, ICU Support Offices, St Thomas’ Hospital, London, United Kingdom

3. Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Departments of Medicine and Anesthesia and Cardiovascular Research Institute, University of California, San Francisco

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2761313/jama_shankarhari_2020_ed_190133.pdf

Reference15 articles.

1. Acute respiratory distress syndrome.;Matthay;Nat Rev Dis Primers,2019

2. Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function.;Narravula;J Immunol,2000

3. Extracellular adenosine-induced Rac1 activation in pulmonary endothelium: molecular mechanisms and barrier-protective role.;Kovacs-Kasa;J Cell Physiol,2018

4. Integrating molecular pathogenesis and clinical translation in sepsis-induced acute respiratory distress syndrome.;Englert;JCI Insight,2019

5. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.;Bellingan;Lancet Respir Med,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute respiratory distress syndrome;The Lancet;2021-08

2. NAloxone CARdiac Arrest Decision Instruments (NACARDI) for targeted antidotal therapy in occult opioid overdose precipitated cardiac arrest;Resuscitation;2021-02

3. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review;Pulmonology;2021-01

4. Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome;New England Journal of Medicine;2020-10-22